FDA Eases Up On Part 11 Scope, Pulls Old Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA will scale back enforcement of its electronic records and signatures rule (Part 11) for all FDA-regulated products while it reassesses the regulation in light of the agency's current good manufacturing practice initiative for drugs and biologics